Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
📧 Sign up to get email alerts when something new happens for Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 clinical trial evaluating Rituximab plus Bendamustine and ibrutinib (PCI-32765) in relapsed DLBCL, mantle cell lymphoma, and various…
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma [Phase 2]
This is a Phase II clinical trial evaluating chlorambucil with subcutaneous rituximab in patients with extranodal MALT lymphoma; the study s…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma [Phase 1]
This update outlines a Phase 1 study of genetically modified T-cell infusions following peripheral blood stem cell transplant for patients w…
-
CLINICAL_TRIALS trial_result · 2025-04-11Clinical Trial Update: Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating mosunetuzumab with or without polatuzumab vedotin and obinutuzumab for untreated indolent B-cell non-Hod…
-
CLINICAL_TRIALS trial_result · 2020-03-23Clinical Trial Update: Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating everolimus and lenalidomide in relapsed or refractory non-Hodgkin or Hodgkin lymphoma; results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-06-06Clinical Trial Update: Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [Phase 2]
Phase 2 study evaluating alisertib with or without rituximab in relapsed or refractory B-cell non-Hodgkin lymphomas was terminated; results …
-
CLINICAL_TRIALS trial_result · 2017-09-29Clinical Trial Update: A Phase I/II Study of Intratumoral Injection of SD-101 [Phase 1, Phase 2]
Phase I/II trial investigating intratumoral SD-101 for various B-cell lymphomas; study completed with results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-06-29Clinical Trial Update: Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies [Phase 2]
A Phase 2 trial evaluating a combination of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with previously treated lymph…
-
CLINICAL_TRIALS trial_result · 2017-01-27Clinical Trial Update: Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial evaluating a conditioning regimen with Iodine-131 tositumomab plus etoposide and cyclophosphamide, followed by autolo…
-
CLINICAL_TRIALS trial_result · 2016-09-07Clinical Trial Update: Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma [Phase 2]
This is a Phase 2 trial evaluating bendamustine plus rituximab as initial therapy for previously untreated extranodal MALT lymphoma; the stu…
-
CLINICAL_TRIALS trial_result · 2015-12-17Clinical Trial Update: Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating a radiolabeled monoclonal antibody with rituximab, with/without filgrastim and interleukin-11, in relapsed or r…
-
CLINICAL_TRIALS trial_result · 2015-06-08Clinical Trial Update: Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial completion evaluating a fusion protein cytokine therapy after Rituximab in patients with B-cell non-Hodgkin lymphomas.
-
CLINICAL_TRIALS trial_result · 2015-04-15Clinical Trial Update: Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease [Phase 2]
Phase 2 trial update reporting completion of a study evaluating interleukin-12 in patients with various previously treated non-Hodgkin lymph…
-
CLINICAL_TRIALS trial_result · 2015-02-18Clinical Trial Update: Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 trial evaluating Rituximab with chemotherapy and 90-yttrium ibritumomab tiuxetan in patients with Stage I or II non-Hodgkin lympho…
-
CLINICAL_TRIALS trial_result · 2014-09-01Clinical Trial Update: Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating agatolimod sodium in combination with rituximab and Yttrium-90 ibritumomab tiuxetan for adults with re…
-
CLINICAL_TRIALS trial_result · 2014-08-06Clinical Trial Update: Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 trial update evaluating the combination of iodine-131 tositumomab with fludarabine phosphate in older patients undergoing autologous…
-
CLINICAL_TRIALS trial_result · 2014-02-24Clinical Trial Update: Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction [Phase 1]
Phase 1 trial of vorinostat in adults with metastatic or unresectable solid tumors or lymphoma and liver dysfunction has completed.
-
CLINICAL_TRIALS trial_result · 2014-02-11Clinical Trial Update: CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 2]
A Phase 2 clinical trial evaluating CCI-779 (temsirolimus) in patients with recurrent or refractory B-cell non-Hodgkin lymphoma or chronic l…
-
CLINICAL_TRIALS trial_result · 2014-01-07Clinical Trial Update: FAU in Treating Patients With Advanced Solid Tumors or Lymphoma [Phase 1]
Phase 1 trial evaluating FAU in patients with advanced solid tumors or lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2013-12-16Clinical Trial Update: Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 trial of a geldanamycin analogue in patients with advanced solid tumors or Non-Hodgkin lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2013-09-30Clinical Trial Update: 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma [Phase 1]
Phase 1 trial evaluating Triapine (3-AP) in combination with gemcitabine in patients with advanced solid tumors or lymphoma has completed. I…
-
CLINICAL_TRIALS trial_result · 2013-09-30Clinical Trial Update: Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 trial evaluating bortezomib and fludarabine with or without rituximab in relapsed or refractory indolent non-Hodgkin lymphoma or chr…
-
CLINICAL_TRIALS trial_result · 2013-08-26Clinical Trial Update: Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating rituximab with interleukin-12 in several B-cell non-Hodgkin lymphomas. The study status is completed.
-
CLINICAL_TRIALS trial_result · 2013-06-06Clinical Trial Update: Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer [Phase 1]
Phase 1 trial evaluating rituximab in combination with interleukin-2 in various hematologic cancers has completed.
-
CLINICAL_TRIALS withdrawal · 2013-06-06Clinical Trial Update: Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating obatoclax mesylate in combination with rituximab and bendamustine hydrochloride for relapsed or refrac…